

Accepted Manuscript

SWITCHing from clOpidogrel to prasugrel to protect early inVasive trEatment in acute coRonary syndromes: results of the SWITCH OVER trial

Filippo Ottani, Eti Alessandra Femia, Marco Cattaneo, Luciano Caravita, Chiara Attanasio, Marcello Galvani

PII: S0167-5273(17)34208-0
DOI: doi:[10.1016/j.ijcard.2017.12.055](https://doi.org/10.1016/j.ijcard.2017.12.055)
Reference: IJCA 25809

To appear in: *International Journal of Cardiology*

Received date: 11 July 2017
Revised date: 8 December 2017
Accepted date: 19 December 2017



Please cite this article as: Ottani Filippo, Femia Eti Alessandra, Cattaneo Marco, Caravita Luciano, Attanasio Chiara, Galvani Marcello, SWITCHing from clOpidogrel to prasugrel to protect early inVasive trEatment in acute coRonary syndromes: results of the SWITCH OVER trial, *International Journal of Cardiology* (2017), doi:[10.1016/j.ijcard.2017.12.055](https://doi.org/10.1016/j.ijcard.2017.12.055)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

SWITCHing from clopidogrel to prasugrel to protect early in Vasive trEatment in acute coRonary syndromes: results of the SWITCH OVER trial

Filippo Ottani, MD^{a,c1}

Eti Alessandra Femia, PhD^{b,1}

Marco Cattaneo, MD^{b,1}

Luciano Caravita, MD^{a,1}

Chiara Attanasio, PhD^{a,1}

Marcello Galvani, MD^{a,c1}

^aUnità Operativa di Cardiologia, Morgagni Hospital, Forlì, Italy

^bDipartimento di Scienze della Salute, Università degli Studi di Milano, Italy and
Unità di Medicina 3, Ospedale San Paolo, ASST Santi Paolo e Carlo, Milano, Italy

^cUnità di Ricerca Cardiovascolare, Fondazione Cardiologica "Sacco", Forlì -Italy

¹ "This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation" (this statement applies to all authors)

Sources of funding

We state that our trial was an investigator-driven study supported by the Azienda Unità Sanitaria Locale della Romagna (formerly Azienda Unità Sanitaria Locale di Forlì) and funded in part by an unrestricted grant from Eli Lilly/Daiichi Sankyo (payed via our Institution, i.e. Azienda Unità Sanitaria Locale della Romagna) .

Disclosures

Dr. Ottani reports receiving speaker fees from Boheringher Ingelheim, Astra Zeneca, Sanofi Aventis, and Eli Lilly during the conduct of the study; prof. Cattaneo reports receiving speaker fees from Eli Lilly, Daiichy Sankyo, AstraZeneca, Evolva, Sanofi Aventis and Merck Sharp & Dohme; dr. Galvani reports receiving speaker fees from Eli Lilly, Daiichi Sankyo, Astra Zeneca and Merck Sharp & Dohme. The other authors state that they have no conflict of interest.

Download English Version:

<https://daneshyari.com/en/article/8662429>

Download Persian Version:

<https://daneshyari.com/article/8662429>

[Daneshyari.com](https://daneshyari.com)